Recap: VYNE Therapeutics Q1 Earnings

VYNE Therapeutics (NASDAQ:VYNE) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:00 PM. Here’s what…

VYNE Therapeutics (NASDAQ:VYNE) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

VYNE Therapeutics beat estimated earnings by 43.3%, reporting an EPS of $-1.48 versus an estimate of $-2.61.

Revenue was down $79 thousand from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.27 which was followed by a 13.0% drop in the share price the next day.

Here’s a look at VYNE Therapeutics’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -3.24 -3.06 -3.06 -2.88
EPS Actual -2.97 -2.52 -2.34 1.80
Revenue Estimate 60K 130K 100K 370K
Revenue Actual 6K 167K 126K 178K

To track all earnings releases for VYNE Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Luminar Technologies Stock Jumps On Earnings As Company Reveals Tesla Was Biggest Customer In Q1

Luminar reported first-quarter revenue of $20.97 million, which missed the consensus estimate of $21.14 million, per Benzinga Pro. The company's top-line results were up 45% on a year-over-year basis, but down 5% sequentially. Luminar reported a first-quarter adjusted earnings loss of 19 cents per share, which beat estimates for a loss of 20 cents per share.

LAZR